MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
1.157
+0.037
+3.27%
Opening 11:13 03/17 EDT
OPEN
1.120
PREV CLOSE
1.120
HIGH
1.170
LOW
1.120
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
3.360
52 WEEK LOW
0.8800
MARKET CAP
223.22M
P/E (TTM)
-5.2406
1D
5D
1M
3M
1Y
5Y
1D
Humacyte Is Maintained at Buy by D. Boral Capital
Dow Jones · 2h ago
Humacyte submits MAA for Symvess in Israel for vascular trauma repair
TipRanks · 2h ago
HUMACYTE SUBMITS MARKETING AUTHORIZATION APPLICATION FOR SYMVESS® IN ISRAEL FOR VASCULAR TRAUMA REPAIR
Reuters · 3h ago
Weekly Report: what happened at HUMA last week (0309-0313)?
Weekly Report · 1d ago
Weekly Report: what happened at HUMA last week (0302-0306)?
Weekly Report · 03/09 10:16
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
NASDAQ · 03/06 14:30
Humacyte Management to Present at TD Cowen Annual Healthcare Conference and Barclays Global Healthcare Conference
Reuters · 03/02 13:01
Weekly Report: what happened at HUMA last week (0223-0227)?
Weekly Report · 03/02 10:15
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.